|
|
|
|
| Dear Partners,
|
If you’re looking to accelerate development timelines, access the right patient populations, and reduce execution risk, then Japan and the broader Asia Pacific (JAPAC) region could be the answer to your clinical trial success.
This month, you can meet us “ IQVIA’s JAPAC experts” who are visiting the United States from May 29 – June 4. We can meet and discuss how JAPAC can be strategically integrated into global development plans-from early feasibility through late-phase execution-to drive faster, more confident trial outcomes.
|
|
Why Consider JAPAC now?
|
|
•
|
Recent regulatory change in Japan, including increased flexibility for Global Phase 3 entry (Japan is no longer slow or expensive—it is increasingly fast, cost competitive)
|
|
•
|
Early-phase data generation opportunities in markets such as China and Australia, enabling better development decision-making
|
|
•
|
Rapid early-phase data generation opportunities in markets such as China and Australia.
|
|
•
|
Access to diverse, treatment-naive patient populations to accelerate enrollment
|
|
•
|
IQVIA's deep local presence in JAPAC, seamlessly integrated with global delivery teams
|
|
|
|
|
If this is relevant to your development plans, we request you to please register here by May 30, 2026 so that we can get in touch with you to meet at a mutually convenient time.
|
|
Kind Regards,
|
|
Ai Kawana
|
Business Development Manager
IQVIA Biotech, JAPAC
|
|
